Crescent Biopharma Estimates $171.6M Cash as of June 30

Crescent Biopharma, Inc. announced preliminary unaudited financial information, estimating its cash and cash equivalents at approximately $171.6 million as of June 30, 2026. The company noted that this data is based on management estimates and is subject to completion of financial closing procedures. PricewaterhouseCoopers LLP has not audited, reviewed, or applied agreed-upon procedures to this preliminary financial data.